Hu Y, He S, Wang J
Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Zhonghua Yi Xue Za Zhi. 2001 Nov 25;81(22):1377-9.
To search for reliable and quantitative biochemical marker for diagnosis of Alzheimer disease.
ELISA-double enzyme amplification assay was used to detect the total tau and abnormally hyperphosphorylated (p-tau) in cerebrospinal fluid specimens of patients with Alzheimer disease (AD, N = 52, 30 from the Netherlands and 22 from Wuhan and Haikou, China), vascular dementia (VD, N = 46, 18 from the Netherlands and 28 from Haikou), and non-neurological disease (N = 37, 13 from the Netherlands and 24 from Haikou) and of normal elderly controls (N = 56, 26 from the Netherlands, and 30 from Wuan and Haikou).
The measurement of CSF specimens from Netherlands Brain Bank showed that the levels of total tau and p-tau in CSF specimens of AD patients were significantly higher than those in CSF of patients with VD and non-dementia neurological disorders, and of age-matched non-neurological normal controls. With CSF tau > or = 370 pg/ml as the marker for diagnosis of AD, the sensitivity, specificity, reliability as well as differentiation rate of AD from VD were 90.0%, 79.0%, 82.8% and 66.7%, respectively. With CSF p-tau > or = 120 pg/ml as the marker for diagnosis of AD, the sensitivity, specificity, reliability as well as differentiation rate of AD from VD were 93.3%, 89.5%, 90.8%, and 83.3% respectively. The measurement of total and phosphorylated taus in CSF specimens of AD and non-AD patients and normal controls collected in China showed the similar results; and the sensitivity, specificity, reliability as well as differentiation rate of AD from VD were 77.3%, 85.4%, 83.7% and 71.4% with CSF tau > or = 120 pg/ml as the marker for diagnosis of AD. There was no correlation between CSF tau and p-tau and age, sex, and seriousness of disease.
Increased phosphorylated tau in human cerebrospinal fluid is a reliable biomarker for diagnosis of Alzheimer disease.
寻找用于诊断阿尔茨海默病的可靠定量生化标志物。
采用酶联免疫吸附双酶扩增法检测阿尔茨海默病患者（AD，n = 52，其中30例来自荷兰，22例来自中国武汉和海口）、血管性痴呆患者（VD，n = 46，其中18例来自荷兰，28例来自海口）、非神经系统疾病患者（n = 37，其中13例来自荷兰，24例来自海口）以及正常老年对照者（n = 56，其中26例来自荷兰，30例来自武汉和海口）脑脊液标本中的总tau蛋白和异常高磷酸化tau蛋白（p-tau）。
对荷兰脑库的脑脊液标本检测显示，AD患者脑脊液标本中总tau蛋白和p-tau蛋白水平显著高于VD患者、非痴呆神经系统疾病患者以及年龄匹配的非神经系统正常对照者。以脑脊液tau≥370 pg/ml作为AD诊断标志物时，AD诊断的敏感性、特异性、可靠性以及AD与VD的鉴别率分别为90.0%、79.0%、82.8%和66.7%。以脑脊液p-tau≥120 pg/ml作为AD诊断标志物时，AD诊断的敏感性、特异性、可靠性以及AD与VD的鉴别率分别为93.3%、89.5%、90.8%和83.3%。对在中国收集的AD患者、非AD患者及正常对照者脑脊液标本中总tau蛋白和磷酸化tau蛋白的检测显示了相似结果；以脑脊液tau≥120 pg/ml作为AD诊断标志物时，AD诊断的敏感性、特异性、可靠性以及AD与VD的鉴别率分别为77.3%、85.4%、83.7%和71.4%。脑脊液tau蛋白和p-tau蛋白与年龄、性别及疾病严重程度均无相关性。
人脑脊液中磷酸化tau蛋白水平升高是诊断阿尔茨海默病的可靠生物标志物。
